GILDGilead Sciences, Inc.
$129.88
$2.85
(2.15%)
EarningsAug 4
Mkt Cap$164.79B
Vol464,896.00
Gilead to Report Q2 Earnings: How Should You Play the Stock Now?
GILD heads into Q2 earnings with HIV franchise strength, rising Yeztugo expectations and oncology progress, even as Cell Therapy faces competitive pressure.
Zacks
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Gilead Sciences (GILD) reached $134.32 at the closing of the latest trading day, reflecting a +2.91% change compared to its last close.
Zacks
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving 1.18% from the previous trading session.
Zacks
CHMP Recommends Gileads Trodelvy Plus Keytruda in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda...
Business Wire
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?
GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.
Zacks
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gileads management will host a webcast to discuss the companys second quarter...
Business Wire
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (AIDS 2026) taking place in Rio de Janeiro, Brazil, from July 26-31. As a leader in HIV innovation, Gilead will share new scientific data from its HIV research and development...
Business Wire
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The...
Business Wire
<
1
2
>
Advertisement|Remove ads.
LMND2
6
NBIS13
20
SOFI7
10Advertisement|Remove ads.